English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksZydus Lifesciences shares fall 2.97% amid volume surge; stock among top losers on Nifty Next 50

    Zydus Lifesciences shares fall 2.97% amid volume surge; stock among top losers on Nifty Next 50

    With the stock currently trading at Rs 989, Zydus Lifesciences experiences a notable downturn amid high trading volume, with the stock among the top losers on the Nifty Next 50 index.

    Alpha Desk
    September 26, 2025 / 12:08 IST
    Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
     
     
    live
    • bselive
    • nselive
    Volume
    Todays L/H
    More

    Shares of Zydus Lifesciences were trading lower on Friday, with the stock priced at Rs 989, a decline of 2.97% at 11:58 am. The stock is among the top losers on the Nifty Next 50 index amid high trading volume.

    Financial Performance:

    The following table presents the consolidated quarterly financial performance of Zydus Lifesciences:

    HeadingJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
    RevenueRs 6,207.50 CroreRs 5,237.00 CroreRs 5,269.10 CroreRs 6,527.90 CroreRs 6,573.70 Crore
    Net ProfitRs 1,463.60 CroreRs 898.10 CroreRs 1,004.30 CroreRs 1,248.80 CroreRs 1,486.60 Crore
    EPS14.119.0610.1711.6414.58

    The revenue for the quarter-ending June 2025 stood at Rs 6,573.70 Crore, compared to Rs 6,207.50 Crore in June 2024. Net profit for the same period was Rs 1,486.60 Crore, up from Rs 1,463.60 Crore in the corresponding quarter of the previous year. The company's EPS stood at 14.58 in June 2025, up from 14.11 in June 2024.

    The following table presents the consolidated yearly financial performance:

    Heading20212022202320242025
    RevenueRs 14,403.50 CroreRs 15,265.20 CroreRs 17,237.40 CroreRs 19,547.40 CroreRs 23,241.50 Crore
    Net ProfitRs 2,205.60 CroreRs 2,326.40 CroreRs 2,001.90 CroreRs 3,831.40 CroreRs 4,614.80 Crore
    EPS20.8443.8319.3038.1444.97
    BVPS145.80186.07194.55219.70238.10
    ROE16.4226.3911.1919.4618.89
    Debt to Equity0.350.250.070.040.13

    The revenue for the year-ending March 2025 was Rs 23,241.50 Crore, an increase compared to Rs 19,547.40 Crore in 2024. The net profit for the year-ending March 2025 was Rs 4,614.80 Crore, up from Rs 3,831.40 Crore in the previous year. The company's EPS stood at 44.97 in March 2025, up from 38.14 in March 2024.

    Income Statement:

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    SalesRs 23,241 CroreRs 19,547 CroreRs 17,237 CroreRs 15,265 CroreRs 14,403 Crore
    Other IncomeRs 269 CroreRs 284 CroreRs 186 CroreRs 224 CroreRs 45 Crore
    Total IncomeRs 23,511 CroreRs 19,831 CroreRs 17,424 CroreRs 15,489 CroreRs 14,449 Crore
    Total ExpenditureRs 17,318 CroreRs 14,941 CroreRs 14,704 CroreRs 12,524 CroreRs 11,891 Crore
    EBITRs 6,192 CroreRs 4,890 CroreRs 2,719 CroreRs 2,965 CroreRs 2,558 Crore
    InterestRs 165 CroreRs 81 CroreRs 129 CroreRs 127 CroreRs 158 Crore
    TaxRs 1,411 CroreRs 977 CroreRs 587 CroreRs 511 CroreRs 193 Crore
    Net ProfitRs 4,614 CroreRs 3,831 CroreRs 2,001 CroreRs 2,326 CroreRs 2,205 Crore

    The company's sales increased from Rs 19,547 Crore in March 2024 to Rs 23,241 Crore in March 2025. The net profit also increased from Rs 3,831 Crore in March 2024 to Rs 4,614 Crore in March 2025.

    Cash Flow:

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Operating ActivitiesRs 6,776 CroreRs 3,227 CroreRs 2,688 CroreRs 2,104 CroreRs 3,293 Crore
    Investing ActivitiesRs -8,372 CroreRs -1,475 CroreRs 1,171 CroreRs 1,154 CroreRs -724 Crore
    Financing ActivitiesRs 2,014 CroreRs -1,810 CroreRs -4,400 CroreRs -868 CroreRs -2,547 Crore
    OthersRs -4 CroreRs -17 CroreRs 6 CroreRs -17 CroreRs -112 Crore
    Net Cash FlowRs 413 CroreRs -74 CroreRs -533 CroreRs 2,372 CroreRs -90 Crore
    Balance Sheet:
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Share CapitalRs 100 CroreRs 100 CroreRs 101 CroreRs 102 CroreRs 102 Crore
    Reserves & SurplusRs 23,852 CroreRs 19,728 CroreRs 17,414 CroreRs 16,897 CroreRs 12,889 Crore
    Current LiabilitiesRs 9,041 CroreRs 5,341 CroreRs 5,530 CroreRs 7,839 CroreRs 7,861 Crore
    Other LiabilitiesRs 4,206 CroreRs 4,109 CroreRs 2,709 CroreRs 2,956 CroreRs 3,031 Crore
    Total LiabilitiesRs 37,201 CroreRs 29,280 CroreRs 25,756 CroreRs 27,795 CroreRs 23,884 Crore
    Fixed AssetsRs 10,583 CroreRs 9,525 CroreRs 7,917 CroreRs 7,549 CroreRs 7,569 Crore
    Current AssetsRs 17,046 CroreRs 11,501 CroreRs 10,016 CroreRs 12,261 CroreRs 8,716 Crore
    Other AssetsRs 9,572 CroreRs 8,253 CroreRs 7,822 CroreRs 7,984 CroreRs 7,599 Crore
    Total AssetsRs 37,201 CroreRs 29,280 CroreRs 25,756 CroreRs 27,795 CroreRs 23,884 Crore
    Contingent LiabilitiesRs 1,428 CroreRs 1,277 CroreRs 1,315 CroreRs 1,210 CroreRs 1,295 Crore
    Financial Ratios:
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Basic EPS (Rs.)44.9738.1419.3043.8320.84
    Diluted Eps (Rs.)44.9738.1419.3043.8320.84
    Book Value [Excl. Reval Reserve]/Share (Rs.)238.10219.70194.55186.07145.80
    Dividend/Share (Rs.)11.003.006.002.503.50
    Face Value11111
    Gross Profit Margin (%)31.5228.9923.4723.3523.83
    Operating Margin (%)27.5825.0819.2818.6819.18
    Net Profit Margin (%)19.8519.7111.5829.9514.84
    Return on Networth / Equity (%)18.8919.4611.1926.3916.42
    ROCE (%)22.7720.4816.4314.2917.24
    Return On Assets (%)12.1613.187.6116.148.93
    Current Ratio (X)1.892.151.811.561.11
    Quick Ratio (X)1.451.511.191.090.70
    Debt to Equity (x)0.130.040.070.250.35
    Interest Coverage Ratios (X)44.1769.8131.1528.0721.62
    Asset Turnover Ratio (%)0.700.710.640.380.37
    Inventory Turnover Ratio (X)6.291.341.161.021.03
    3 Yr CAGR Sales (%)23.3916.509.977.689.99
    3 Yr CAGR Net Profit (%)40.8431.8030.4912.0811.74
    P/E (x)19.7126.4125.477.9521.16
    P/B (x)3.725.102.842.103.47
    EV/EBITDA (x)12.5218.1812.9711.4614.79
    P/S (x)3.835.172.892.343.13
    Corporate Actions:

    Zydus Lifesciences announced a final dividend of Rs 11.00 per share, with effective date as July 25, 2025. Earlier dividends include Rs 3.00 per share on July 26, 2024, Rs 6.00 per share on July 28, 2023, Rs 2.50 per share on July 28, 2022, and Rs 3.50 per share on July 28, 2021.

    The company had a stock split on October 6, 2015, with old FV of 5 and new FV of 1.

    Zydus Lifesciences had bonus issues with ex-bonus dates on April 5, 2010 and August 30, 2006.

    Moneycontrol analysis indicates a bullish sentiment on Zydus Lifesciences as of September 25, 2025.

    With the stock currently trading at Rs 989, Zydus Lifesciences experiences a notable downturn amid high trading volume, with the stock among the top losers on the Nifty Next 50 index.

    Alpha Desk
    first published: Sep 26, 2025 12:08 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347